Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
3.
Parasite Immunol ; 45(4): e12970, 2023 04.
Article in English | MEDLINE | ID: mdl-36655799

ABSTRACT

The pathophysiology of schistosomiasis is linked to the formation of fibrous granulomas around eggs that become trapped in host tissues, particularly the intestines and liver, during their migration to reach the lumen of the vertebrate gut. While the development of Schistosoma egg-induced granulomas is the result of finely regulated crosstalk between egg-secreted antigens and host immunity, evidence has started to emerge of the likely contribution of an additional player-the host gut microbiota-to pathological processes that culminate with the formation of these tissue lesions. Uncovering the role(s) of schistosome-mediated changes in gut microbiome composition and function in granuloma formation and, more broadly, in the pathophysiology of schistosomiasis, will shed light on the mechanisms underlying this three-way parasite-host-microbiome interplay. Such knowledge may, in turn, pave the way towards the discovery of novel therapeutic targets and control strategies.


Subject(s)
Gastrointestinal Microbiome , Schistosomiasis mansoni , Schistosomiasis , Animals , Humans , Schistosoma mansoni , Liver , Granuloma/pathology
4.
Front Immunol ; 13: 906338, 2022.
Article in English | MEDLINE | ID: mdl-35958580

ABSTRACT

Schistosomiasis is a disease of global significance, with severity and pathology directly related to how the host responds to infection. The immunological narrative of schistosomiasis has been constructed through decades of study, with researchers often focussing on isolated time points, cell types and tissue sites of interest. However, the field currently lacks a comprehensive and up-to-date understanding of the immune trajectory of schistosomiasis over infection and across multiple tissue sites. We have defined schistosome-elicited immune responses at several distinct stages of the parasite lifecycle, in three tissue sites affected by infection: the liver, spleen, and mesenteric lymph nodes. Additionally, by performing RNA-seq on the livers of schistosome infected mice, we have generated novel transcriptomic insight into the development of schistosome-associated liver pathology and fibrosis across the breadth of infection. Through depletion of CD11c+ cells during peak stages of schistosome-driven inflammation, we have revealed a critical role for CD11c+ cells in the co-ordination and regulation of Th2 inflammation during infection. Our data provide an updated and high-resolution account of how host immune responses evolve over the course of murine schistosomiasis, underscoring the significance of CD11c+ cells in dictating host immunopathology against this important helminth infection.


Subject(s)
Schistosomiasis mansoni , Schistosomiasis , Animals , CD11c Antigen , Immunity , Inflammation , Mice , Schistosoma mansoni
5.
Immunohorizons ; 5(8): 721-732, 2021 08 30.
Article in English | MEDLINE | ID: mdl-34462311

ABSTRACT

Plasmacytoid dendritic cells (pDCs) are potent producers of type I IFN (IFN-I) during viral infection and respond to IFN-I in a positive feedback loop that promotes their function. IFN-I shapes dendritic cell responses during helminth infection, impacting their ability to support Th2 responses. However, the role of pDCs in type 2 inflammation is unclear. Previous studies have shown that pDCs are dispensable for hepatic or splenic Th2 responses during the early stages of murine infection with the trematode Schistosoma mansoni at the onset of parasite egg laying. However, during S. mansoni infection, an ongoing Th2 response against mature parasite eggs is required to protect the liver and intestine from acute damage and how pDCs participate in immune responses to eggs and adult worms in various tissues beyond acute infection remains unclear. We now show that pDCs are required for optimal Th2 cytokine production in response to S. mansoni eggs in the intestinal-draining mesenteric lymph nodes throughout infection and for egg-specific IFN-γ at later time points of infection. Further, pDC depletion at chronic stages of infection led to increased hepatic and splenic pathology as well as abrogated Th2 cell cytokine production and activation in the liver. In vitro, mesenteric lymph node pDCs supported Th2 cell responses from infection-experienced CD4+ T cells, a process dependent on pDC IFN-I responsiveness, yet independent of Ag. Together, these data highlight a previously unappreciated role for pDCs and IFN-I in maintaining and reinforcing type 2 immunity in the lymph nodes and inflamed tissue during helminth infection.


Subject(s)
Cytokines/immunology , Dendritic Cells/immunology , Lymphocyte Activation/immunology , Schistosoma mansoni/immunology , Schistosomiasis mansoni/immunology , T-Lymphocytes, Helper-Inducer/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/parasitology , Cytokines/metabolism , Dendritic Cells/parasitology , Female , Flow Cytometry/methods , Host-Parasite Interactions/immunology , Lymphocyte Count , Mice, Inbred C57BL , Mice, Knockout , Schistosoma mansoni/physiology , Schistosomiasis mansoni/metabolism , Schistosomiasis mansoni/parasitology , T-Lymphocytes, Helper-Inducer/metabolism , T-Lymphocytes, Helper-Inducer/parasitology , Th2 Cells/immunology , Th2 Cells/metabolism , Th2 Cells/parasitology
6.
Front Immunol ; 12: 635513, 2021.
Article in English | MEDLINE | ID: mdl-33953712

ABSTRACT

Schistosome infection is a major cause of global morbidity, particularly in sub-Saharan Africa. However, there is no effective vaccine for this major neglected tropical disease, and re-infection routinely occurs after chemotherapeutic treatment. Following invasion through the skin, larval schistosomula enter the circulatory system and migrate through the lung before maturing to adulthood in the mesenteric or urogenital vasculature. Eggs released from adult worms can become trapped in various tissues, with resultant inflammatory responses leading to hepato-splenic, intestinal, or urogenital disease - processes that have been extensively studied in recent years. In contrast, although lung pathology can occur in both the acute and chronic phases of schistosomiasis, the mechanisms underlying pulmonary disease are particularly poorly understood. In chronic infection, egg-mediated fibrosis and vascular destruction can lead to the formation of portosystemic shunts through which eggs can embolise to the lungs, where they can trigger granulomatous disease. Acute schistosomiasis, or Katayama syndrome, which is primarily evident in non-endemic individuals, occurs during pulmonary larval migration, maturation, and initial egg-production, often involving fever and a cough with an accompanying immune cell infiltrate into the lung. Importantly, lung migrating larvae are not just a cause of inflammation and pathology but are a key target for future vaccine design. However, vaccine efforts are hindered by a limited understanding of what constitutes a protective immune response to larvae. In this review, we explore the current understanding of pulmonary immune responses and inflammatory pathology in schistosomiasis, highlighting important unanswered questions and areas for future research.


Subject(s)
Lung Diseases, Parasitic/parasitology , Lung/parasitology , Schistosoma/pathogenicity , Schistosomiasis/parasitology , Animals , Disease Models, Animal , Host-Parasite Interactions , Humans , Immune Evasion , Lung/drug effects , Lung/immunology , Lung Diseases, Parasitic/immunology , Lung Diseases, Parasitic/prevention & control , Mice , Protozoan Vaccines/therapeutic use , Schistosoma/drug effects , Schistosoma/immunology , Schistosomiasis/immunology , Schistosomiasis/prevention & control , Schistosomicides/therapeutic use
7.
Front Immunol ; 11: 593838, 2020.
Article in English | MEDLINE | ID: mdl-33329584

ABSTRACT

In spite of growing evidence supporting the occurrence of complex interactions between Schistosoma and gut bacteria in mice and humans, no data is yet available on whether worm-mediated changes in microbiota composition are dependent on the baseline gut microbial profile of the vertebrate host. In addition, the impact of such changes on the susceptibility to, and pathophysiology of, schistosomiasis remains largely unexplored. In this study, mice colonized with gut microbial populations from a human donor (HMA mice), as well as microbiota-wild type (WT) animals, were infected with Schistosoma mansoni, and alterations of their gut microbial profiles at 50 days post-infection were compared to those occurring in uninfected HMA and WT rodents, respectively. Significantly higher worm and egg burdens, together with increased specific antibody responses to parasite antigens, were observed in HMA compared to WT mice. These differences were associated to extensive dissimilarities between the gut microbial profiles of each HMA and WT groups of mice at baseline; in particular, the gut microbiota of HMA animals was characterized by low microbial alpha diversity and expanded Proteobacteria, as well as by the absence of putative immunomodulatory bacteria (e.g. Lactobacillus). Furthermore, differences in infection-associated changes in gut microbiota composition were observed between HMA and WT mice. Altogether, our findings support the hypothesis that susceptibility to S.mansoni infection in mice is partially dependent on the composition of the host baseline microbiota. Moreover, this study highlights the applicability of HMA mouse models to address key biological questions on host-parasite-microbiota relationships in human helminthiases.


Subject(s)
Gastrointestinal Microbiome , Host-Parasite Interactions , Parasite Load , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/parasitology , Animals , Antibodies, Protozoan/immunology , Bacteria/classification , Bacteria/genetics , Biodiversity , Computational Biology/methods , Disease Models, Animal , Dysbiosis , Feces/microbiology , Gastrointestinal Microbiome/immunology , Host-Parasite Interactions/immunology , Immunomodulation , Metagenomics/methods , Mice , RNA, Ribosomal, 16S , Schistosoma
8.
Mol Nutr Food Res ; 64(15): e1900732, 2020 08.
Article in English | MEDLINE | ID: mdl-31389129

ABSTRACT

SCOPE: Akkermansia muciniphila (A. muciniphila) is an intestinal commensal with anti-inflammatory properties both in the intestine and other organs. The aim is to investigate the effects of oral administration of A. muciniphila on lipid metabolism, immunity, and cuff-induced neointima formation in hyperlipidemic APOE*3-Leiden (E3L).CETP mice. METHODS AND RESULTS: Hyperlipidemic male E3L.CETP mice are daily treated with 2 × 108 CFU A. muciniphila by oral gavage for 4 weeks and the effects are determined on plasma lipid levels, immune parameters, and cuff-induced neointima formation and composition. A. muciniphila administration lowers body weight and plasma total cholesterol and triglycerides levels. A. muciniphila influences the immune cell composition in mesenteric lymph nodes, as evident from an increased total B cell population, while reducing the total T cell and neutrophil populations. Importantly, A. muciniphila reduces the expression of the activation markers MHCII on dendritic cells and CD86 on B cells. A. muciniphila also increases whole blood ex vivo lipopolysaccharide-stimulated IL-10 release. Finally, although treatment with A. muciniphila improves lipid metabolism and immunity, it does not affect neointima formation or composition. CONCLUSIONS: Four weeks of treatment with A. muciniphila exerts lipid-lowering and immunomodulatory effects, which are insufficient to inhibit neointima formation in hyperlipidemic E3L.CETP mice.


Subject(s)
Hyperlipidemias/therapy , Immunologic Factors/pharmacology , Lipids/blood , Probiotics/administration & dosage , Administration, Oral , Akkermansia/immunology , Akkermansia/physiology , Animals , Apolipoprotein E3/genetics , Disease Models, Animal , Hypercholesterolemia/immunology , Hypercholesterolemia/metabolism , Hypercholesterolemia/therapy , Hyperlipidemias/immunology , Hyperlipidemias/metabolism , Lipid Metabolism , Lipopolysaccharides/blood , Lymph Nodes/immunology , Male , Mice, Mutant Strains , Neointima/etiology , Neointima/prevention & control
9.
Eur J Immunol ; 49(8): 1226-1234, 2019 08.
Article in English | MEDLINE | ID: mdl-31099896

ABSTRACT

The helminth Schistosoma mansoni (S. mansoni) induces a network of regulatory immune cells, including interleukin (IL)-10-producing regulatory B cells (Bregs). However, the signals required for the development and activation of Bregs are not well characterized. Recent reports suggest that helminths induce type I interferons (IFN-I), and that IFN-I drive the development of Bregs in humans. We therefore assessed the role of IFN-I in the induction of Bregs by S. mansoni. Mice chronically infected with S. mansoni or i.v. injected with S. mansoni soluble egg antigen (SEA) developed a systemic IFN-I signature. Recombinant IFN-α enhanced IL-10 production by Bregs stimulated with S. mansoni SEA in vitro, while not activating Bregs by itself. IFN-I signaling also supported ex vivo IL-10 production by SEA-primed Bregs but was dispensable for activation of S. mansoni egg-induced Bregs in vivo. These data indicate that although IFN-I can serve as a coactivator for Breg IL-10 production, they are unlikely to participate in the development of Bregs in response to S. mansoni eggs.


Subject(s)
B-Lymphocytes, Regulatory/immunology , Interferon Type I/metabolism , Schistosoma mansoni/physiology , Schistosomiasis mansoni/immunology , Animals , Antigens, Helminth/immunology , Cells, Cultured , Disease Models, Animal , Eggs , Female , Flow Cytometry , Humans , Interleukin-10/metabolism , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Signal Transduction
10.
Front Immunol ; 10: 749, 2019.
Article in English | MEDLINE | ID: mdl-31031753

ABSTRACT

[This corrects the article DOI: 10.3389/fimmu.2018.03042.].

11.
Nat Commun ; 9(1): 3797, 2018 09 18.
Article in English | MEDLINE | ID: mdl-30228258

ABSTRACT

Inflammatory bowel disease (IBD) are heterogenous disorders of the gastrointestinal tract caused by a spectrum of genetic and environmental factors. In mice, overlapping regions of chromosome 3 have been associated with susceptibility to IBD-like pathology, including a locus called Hiccs. However, the specific gene that controls disease susceptibility remains unknown. Here we identify a Hiccs locus gene, Alpk1 (encoding alpha kinase 1), as a potent regulator of intestinal inflammation. In response to infection with the commensal pathobiont Helicobacter hepaticus (Hh), Alpk1-deficient mice display exacerbated interleukin (IL)-12/IL-23 dependent colitis characterized by an enhanced Th1/interferon(IFN)-γ response. Alpk1 controls intestinal immunity via the hematopoietic system and is highly expressed by mononuclear phagocytes. In response to Hh, Alpk1-/- macrophages produce abnormally high amounts of IL-12, but not IL-23. This study demonstrates that Alpk1 promotes intestinal homoeostasis by regulating the balance of type 1/type 17 immunity following microbial challenge.


Subject(s)
Colitis/immunology , Helicobacter Infections/immunology , Inflammatory Bowel Diseases/immunology , Interleukin-12/immunology , Protein Kinases/metabolism , Th1 Cells/immunology , Animals , Bone Marrow Cells , Bone Marrow Transplantation , Colitis/microbiology , Colitis/pathology , Colon , Disease Models, Animal , Female , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter hepaticus/immunology , Humans , Inflammatory Bowel Diseases/microbiology , Inflammatory Bowel Diseases/pathology , Interleukin-12/metabolism , Interleukin-23/immunology , Interleukin-23/metabolism , Macrophages/immunology , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Primary Cell Culture , Protein Kinases/genetics , Protein Kinases/immunology , Radiation Chimera , Th1 Cells/metabolism
12.
Front Immunol ; 9: 3042, 2018.
Article in English | MEDLINE | ID: mdl-30619372

ABSTRACT

Many parasitic worms possess complex and intriguing life cycles, and schistosomes are no exception. To exit the human body and progress to their successive snail host, Schistosoma mansoni eggs must migrate from the mesenteric vessels, across the intestinal wall and into the feces. This process is complex and not always successful. A vast proportion of eggs fail to leave their definite host, instead becoming lodged within intestinal or hepatic tissue, where they can evoke potentially life-threatening pathology. Thus, to maximize the likelihood of successful egg passage whilst minimizing host pathology, intriguing egg exit strategies have evolved. Notably, schistosomes actively exert counter-inflammatory influences on the host immune system, discreetly compromise endothelial and epithelial barriers, and modulate granuloma formation around transiting eggs, which is instrumental to their migration. In this review, we discuss new developments in our understanding of schistosome egg migration, with an emphasis on S. mansoni and the intestine, and outline the host-parasite interactions that are thought to make this process possible. In addition, we explore the potential immune implications of egg penetration and discuss the long-term consequences for the host of unsuccessful egg transit, such as fibrosis, co-infection and cancer development.


Subject(s)
Endothelium, Vascular/immunology , Host-Parasite Interactions/immunology , Intestinal Mucosa/immunology , Ovum/immunology , Schistosoma mansoni/immunology , Animals , Antigens, Helminth/immunology , Antigens, Helminth/metabolism , Disease Models, Animal , Endothelium, Vascular/parasitology , Feces/parasitology , Humans , Intestinal Mucosa/parasitology , Mesenteric Arteries/immunology , Mesenteric Arteries/parasitology , Mesenteric Veins/immunology , Mesenteric Veins/parasitology , Ovum/metabolism , Peyer's Patches/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...